Gina Lee Barrientos, PharmD, RPh

Are your #MedicalAffairs teams reaching all the providers who need your support? Learn how to transform your outreach strategies with data-driven insights powered by real-world patient journey data. Read more. ⬇️

7

Danielle L. Hagen, Clinical Supply Manager at Nykode Therapeutics, is stealing the spotlight with her presentation on "Designing a Robust Supply Chain Strategy for Individualized Vaccines" at the 3rd BioPharma Supply Chain & Logistics Nexus Conference! 🎤 Don't miss this opportunity to gain valuable knowledge and network with industry leaders. See you there! 💼✨ #BioPharma #SupplyChain #Logistics #NexusConference #SupplyManagement #LivePresentation 🌐📢

29

📈 Biopharma's Q1 2024 Earnings: Winners & Losers 📉 The first quarter of 2024 showcased significant trends in the biopharma industry, with some companies soaring while others faced challenges. Here's a roundup of the winners and losers based on Q1 results! 💼💰 Winners: 🥇 Amgen: Reported solid Q1 financial results, with total revenues of $7.4 billion, driven by product sales growth of 22%. The integration of sales from Horizon' acquisition contributed significantly. 🥈 AstraZeneca: Total revenue surged by 19% to $12.6 billion, fuelled by strong performance in oncology and cardiovascular divisions, especially in emerging markets. 🥉 Novo Nordisk: Posted a 27% increase in operating profit, driven by robust sales in diabetes and obesity care, particularly with GLP-1 products Ozempic and Wegovy. Despite growth, Novo Nordisk's share price dropped by 3%, possibly due to cautious guidance updates. Losers: 👎 Biogen: Faced challenges with declining revenue, particularly in multiple sclerosis products, resulting in a 6.9% YoY drop. The company's transition period includes the redesign of its portfolio and reliance on Leqembi for future revenue. 👎 Bristol Myers Squibb: Despite revenue growth, downgraded EPS guidance and announced layoffs, causing a nearly 8% drop in share price. Patent cliffs and recent acquisitions impact future outlook. 👎 Johnson & Johnson: Missed analyst estimates, with sales growth falling short. Stelara's biosimilar competition adds pressure, despite better-than-expected income. The Q1 earnings season provides valuable insights into the biopharma landscape, showcasing both successes and challenges. Stay tuned for more updates in the industry! 🌐💡 #Biopharma #EarningsSeason #WinnersAndLosers #Healthcare #Finance #BusinessInsights #Pharmaceuticals #Investing #StockMarket #Innovation #Challenges #Opportunities 📊🔬💼

4

1 Comment

🚀 Exciting News from Illumina! 🚀 Illumina is set to spin off its multi-cancer early detection firm, GRAIL, by issuing shares to existing stockholders later this month. 📅 Effective June 24, Illumina will issue one share of Grail for every six shares of Illumina stock, retaining a 14.5% stake in Grail. 🧬💹 Grail will become an independent, publicly traded company, listing on Nasdaq under the ticker symbol "GRAL." With around 31.1 million shares of common stock and an estimated capitalization of $3.99 billion, Grail is poised for a remarkable journey in advancing genomics and improving human health. 🌍🔬 CEO Jacob Thaysen emphasises this milestone as a pivotal step for Illumina: "As we prepare to lead the next era of genomics innovation, we believe Grail will play an important role in advancing the industry and improving human health." This move follows the divestiture orders from the US FTC and European Commission and is aligned with activist investor Carl Icahn's campaign, which led to significant leadership changes within Illumina. 🚀📊 Transaction costs are estimated at $20M for Grail and $60-75M for Illumina, with Grail's cash position post-spinoff bolstered by Illumina’s funding. 💰💼 In after-hours trading, Illumina's shares saw a 2% increase, reflecting positive investor sentiment. 📈💹 #Genomics #HealthcareInnovation #BiotechNews #Investing #NASDAQ #Grail #Illumina #GenomicsRevolution #HealthTech 🚀🔬💼

9

1 Comment

Karen Fancher, PharmD, BCOP, shares insights from her presentation at the HOPA Annual Conference 2024, delving into the ethical complexities faced by oncology pharmacists. From balancing beneficence and non-maleficence to navigating drug shortages, her discussion sheds light on crucial considerations in patient care. Read more about the intersection of science and morals in oncology pharmacy: https://lnkd.in/gpJWG9ZP #OncologyPharmacy #EthicalDilemmas #HealthcareEthics #PharmacyNews

3

As the fate of TikTok remains uncertain, it's a crucial time for brands to rethink their content and channel strategies. Discover how this could impact #PharmaAdvertising and the steps you can take to stay ahead. Explore the insights from Ashley Haden, Media Director, Paid Social at EVERSANA INTOUCH, in Med Ad News. https://ow.ly/raJE50Sh9yS #PharmaMarketing #TikTokBan #DigitalStrategy

17

At #AGBreakthrough Innovators Tokyo, we’re bringing together industry experts and #pharmaceutical executives from Astellas Pharma, Santen, Taiho Oncology, Inc., and more to explore the transformation of intelligent #automation – from the benefits being delivered via out-of-the-box solutions, to the value customers are realizing with #automation, #GenAI, large language models (#LLM), and Real-World Data (#RWD)

35

1 Comment

We invest in the best people to fill our Medical Affairs roles. Invest also in their knowledge and capabilities by engaging with LMA for one of these programs: Insights Metrics Cross Functional Alignment MSL University - Foundations of the MSL Role MLS102 For more information, visit www.lmamap.com #pharmaceuticalindustry #pharmaceuticals #pharmaceutical #pharmaceuticalcompanies #medicalaffairs #medicaldevices #medicaldevice #pharma #pharmamarketing #pharmaindustry #pharma #biotechnologyindustry #biotech #biotechnology #biotechindustry #biotechnologies #biotechstartup #pharmaceuticalsales #pharmaceuticalmarketing

1

Astellas Pharma CEO Q&a (Part 2): We Have To Have Alternatives for Prescription Medicine Business – MedCity News - MedCity News #AstellasPharmaCEOQ&A: In this blog post from MedCity News, the CEO of Astellas Pharma discusses the need for alternatives in the prescription medicine business. The post is divided into several sections, each addressing a specific aspect of the interview. #DigitalTransformation: The CEO emphasizes the importance of digital transformation in healthcare and the pharmaceutical industry. He discusses how technology can improve patient care and outcomes. #Innovation: The CEO highlights the role of innovation in driving growth and success in the pharmaceutical sector. He emphasizes the need for continuous innovation to stay competitive. #PatientCentricity: The CEO stresses the importance of putting patients at the center of healthcare decision-making. He discusses how patient-centric approaches can lead to better outcomes and experiences ai.mediformatica.com #medcity #news #digital #innovation #medicine #pharma #prescription #about #busine #technology #digitaltechnologies #patients #digitalhealth #healthit #healthtech #healthcaretechnology @MediFormatica (https://buff.ly/4af2QbH)

1

Many patients using GLP-1s for weight loss stop treatment within a year. Our newly released research study - featured in CNN by Deidre McPhillips - shows that even the patients who received GLP-1 orders for *at least* a year saw mixed results. This suggests that the real-world efficacy of GLP-1s may be more nuanced than what has been seen in clinical trials. Read the full CNN article here: https://lnkd.in/e6QJirD6 We used our recently launched GLP-1 Data Library to conduct one of the largest real-world studies on GLP-1 usage and efficacy to-date. Among other findings, we saw that: - The top 10% of GLP-1 responders lost up to 15% of their weight by 12 months, compared to almost 5% average weight *gain* in the bottom 10% of responders. - Older adults, women, and people who were diagnosed with obesity but not T2 diabetes at the time of GLP-1 initiation experienced the most weight loss over a 12 month period. As demand for GLP-1 soars, and more clinical trials report GLP-1 benefits beyond weight loss (e.g., for heart and liver health), data and research into real-world use and efficacy will be even more important. Thanks to Deidre McPhillips and the researchers Shivaani Prakash, MSc, PhD and Neil Jethani for shedding light on this important topic. To read the full study and download our latest whitepaper, follow the link in the comments.

36

2 Comments

☕ #Boston, grab you favorite Dunkin’ coffee and join us at the Precision in Clinical Trials Summit May 6 & 7! Stop by Booth #11 to meet the #IDDI experts Tara Kervin & Kalyn D. to discuss how IDDI’s solutions can assist your most pressing clinical trial challenges. 📈 Schedule a meeting today: https://lnkd.in/efjcJffp #PCTSummit #biometricscro #clinicaltrials #biostatistics #datamanagement #lifesciences #trialdesign

10

#News for #Investors and #Media: As the chronic lymphocytic leukemia (CLL) treatment landscape continues to evolve, it’s important to provide new data that can help physicians in making treatment decisions.  During #ASCO24, we will share new comparative effectiveness research underscoring the differentiated clinical profile of our BTK inhibitor in the treatment of #CLL. Learn more here: https://bit.ly/3Kf9t33

182

2 Comments

🎧 #ICYMI: When Lorece Shaw, PharmD (Director, Prior Authorization) joined us for episode 17 of Astonishing Healthcare, she shared a personal story about a situation where she was prescribed twice the recommended dose of a #medication. Thankfully, she was able to catch the mistake due to her experience and speak with the dispensing #pharmacist, but we all know that the healthcare system can be challenging to navigate, even for experienced consumers. In cases like these, #priorauthorization can help as well! You can listen to the entire episode here: https://okt.to/cD4ibx

19

1 Comment

Next week, our Pharmacy Resident, Brittny Nutt, PharmD, will present her poster abstract "Reducing the Copay of Branded Diabetes Drugs Effect on Adherence in a Medicare Prescription Drug Plan Population" at the Southeastern Residency Conference https://bit.ly/446x0MT in Athens, GA. Stop by to view the poster and ask Brittny about her research! #sercpharm2024 #diabetes #medicationadherence #pharmacyresidents

11

2 Comments

In an interview with Pharmaceutical Executive, our CEO, Ying Huang, discusses the promising potential of CAR-T therapies as they move up the #MultipleMyeloma treatment paradigm.     Click here to read the article and learn more about our latest data presented at #ASCO24: https://lnkd.in/eer3kCSx

145

2 Comments